Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Given Average Recommendation of "Buy" by Brokerages theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Citigroup began coverage on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) in a research report sent to investors on Friday, Marketbeat reports. The firm issued a buy rating and a $40.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. Cantor Fitzgerald raised their price objective […]
Longboard Pharmaceuticals (NASDAQ:LBPH) Price Target Raised to $60.00 at Cantor Fitzgerald themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Cantor Fitzgerald Boosts Longboard Pharmaceuticals (NASDAQ:LBPH) Price Target to $60.00 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) had its price target boosted by HC Wainwright from $25.00 to $60.00 in a report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Longboard Pharmaceuticals’ Q4 2023 earnings at ($0.52) EPS, FY2023 earnings at ($2.28) EPS, […]